Background {#Sec1}
==========

*Cornus officinalis* Sieb. et Zucc., commonly known as Shan Zhu Yu/山茱萸 (in Chinese), Asiatic Dogwood, and Japanese Cornel Dogwood, is a deciduous shrub or dungarunga in the genus *Cornus* (family *Cornaceae*). It is a heliophilous plant that grows in the warm-temperate zone. The most suitable growth temperature is between 20 and 30 °C, it also has a specific cold resistance that can temporarily grow in − 18 °C low-temperature zone. *Cornus officinalis* Sieb. et Zucc. can be found in Anhui, Gansu, Jiangsu, Jiangxi, Shandong, Shanxi in China, Korea, and Japan. It usually grows in 400--1500 m high mountain slope, forest or forest edge. Ripening fruits are picked during September and October and dried in the air for medical uses \[[@CR1], [@CR2]\].

About 2200 years ago, *Cornus officinalis* Sieb. et Zucc. fructus (usually known as *Corni Fructus*) was first recorded in *Shen Nong's Materia Medica* (Fig. [1](#Fig1){ref-type="fig"}). According to the basic theory of TCM, CF is characterized as replenishing liver and kidney, arresting seminal emission and sweat for its sour, astringent, and tepid properties \[[@CR1]\]. It is used to treat four series of clinical symptoms. The first part of symptoms contains vertigo, tinnitus, weakness of the waist and knees which are caused by liver and kidney deficiency. CF is usually combined with *Radix Rehmanniae Praeparata*, *Dioscoreae Rhizoma*, *Alismatis Rhizoma*, *Moutan Cortex*, *Poria* to make Liuwei Dihuang Wan (六味地黄丸) replenish liver and kidney Yin \[[@CR3]\]. For patients with kidney Yang deficiency, CF helps *Cinnamomi Cortex*, *Aconiti Lateralis Radix Praeparata* to reinforce Yang from Yin, e.g., Jingui Shenqi Wan (金匮肾气丸) \[[@CR4]\]. The second part of symptoms contains spermatorrhoea and polydipsia. For patients with kidney deficiency, CF is frequently used with *Radix Rehmanniae Praeparata*, *Dioscoreae Rhizoma*, *Cervi Cornu Pantotrichum*, *Psoraleae Fructus*. For patients with dysfunction of the urinary bladder, CF is often applied with *Mantidis Oötheca*, *Rubi Fructus*, *Rosae Laevigatae Fructus*. The third part of symptom contains hypermenorrhea. CF is usually combined with *Radix Rehmanniae Praeparata*, *Angelica Sinensis*, *Radix Paeoniae Alba* to make Guchong Tang (固冲汤) preserve Primordial Qi and stop Blood \[[@CR5]\]. The fourth part of symptoms contains profuse cold sweating, pale complexion, cold limbs, and a feeble pulse. For patients with the Yang depletion syndrome, *Ginseng Radix et Rhizoma*, *Aconiti Lateralis Radix Praeparata*, and CF are applied in Laifu Tang (来复汤) to restore Yang from collapse. Medical practices indicate that CF can be combined with either Yin-tonifying or Yang-invigorating herbs to act as the sovereign drug or adjuvant drug in Chinese medicinal formulae and treat different types of TCM syndromes. Besides, CF is primarily made into the honey bolus to treat chronic diseases while is usually made into the decoction to treat acute conditions.Fig. 1*Corni Fructus*: **a** crude fruits, **b** processed fruits

Chemical constituents {#Sec2}
=====================

About 90 compounds have been isolated and identified from CF, including terpenoids, flavonoids, tannins, polysaccharides, phenylpropanoids, sterols, carboxylic acids, furans, and mineral substances. Chemical constituents are listed in Table [1](#Tab1){ref-type="table"}. Among them, iridoids, tannins, and flavonoids are the major components. Their chemical structures are shown in Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}.Table 1Chemical constituents identified from CFNo.Chemical classCompound nameChemical formulaExact massReferencesTerpenoids1IridoidsSwerosideC~16~H~22~O~9~358.1264\[[@CR73]\]2Loganic acidC~16~H~24~O~10~376.1369\[[@CR19]\]3CorninC~17~H~24~O~10~388.1369\[[@CR73]\]47-DehydrologaninC~17~H~24~O~10~388.1369\[[@CR74]\]5LoganinC~17~H~26~O~10~390.1526\[[@CR74]\]67-α-MorronisideC~17~H~26~O~11~406.1475\[[@CR75]\]77-β-MorronisideC~17~H~26~O~11~406.1475\[[@CR75]\]87-α-*O*-Methyl-morronisideC~18~H~28~O~11~420.1632\[[@CR75]\]97-β-*O*-Methyl-morronisideC~18~H~28~O~11~420.1632\[[@CR75]\]107-α-*O*-Ethyl-morronisideC~18~H~29~O~11~421.1710\[[@CR75]\]117-β-*O*-Ethyl-morronisideC~18~H~29~O~11~421.1710\[[@CR75]\]127-α-*O*-Butyl-morronisideC~21~H~34~O~11~462.2101\[[@CR43]\]137-β-*O*-Dimethyl-butanedioate morronisideC~23~H~34~O~15~550.1898\[[@CR76]\]14Logmalicids AC~21~H~29~O~14~505.1557\[[@CR24]\]15Logmalicids BC~21~H~29~O~14~505.1557\[[@CR24]\]16Cornusfuroside AC~25~H~34~O~13~542.1999\[[@CR77]\]17Cornusfuroside BC~25~H~34~O~13~542.1999\[[@CR77]\]18Cornusfuroside CC~25~H~34~O~13~542.1999\[[@CR77]\]19Cornusfuroside DC~29~H~34~O~15~622.1898\[[@CR77]\]20SecoiridoidsLinaloolC~10~H~18~O154.1358\[[@CR78]\]21Linalool oxideC~10~H~18~O~2~170.1307\[[@CR79]\]22SecoxyloganinC~17~H~24~O~11~404.1319\[[@CR24]\]23CornusideC~24~H~30~O~14~542.1636\[[@CR74]\]24TriterpenoidsUrsolic acidC~30~H~48~O~3~456.3603\[[@CR74]\]25Oleanolic acidC~30~H~48~O~3~456.3603\[[@CR15]\]26Arjunglucoside IIC~36~H~58~O~10~650.4030\[[@CR74]\]Flavonoids27NaringeninC~15~H~12~O~5~272.0685\[[@CR74]\]28KaempferolC~15~H~10~O~6~286.0477\[[@CR79]\]29KaempferideC~16~H~12~O~6~300.0634\[[@CR80]\]30Kaempferol-3-*O*-β-[d]{.smallcaps}-galactopyranosideC~21~H~20~O~11~448.1006\[[@CR24]\]31Kaempferol-3-*O*-β-[d]{.smallcaps}-glucosideC~21~H~20~O~11~448.1006\[[@CR74]\]32Kaempferol-3-*O*-β-[d]{.smallcaps}-rutinosideC~27~H~30~O~15~594.1585\[[@CR24]\]33QuercetinC~15~H~10~O~7~302.0427\[[@CR79]\]34Quercetin-3-*O*-β-[d]{.smallcaps}-galactopyranosideC~21~H~20~O~12~464.0955\[[@CR24]\]35Quercetin-3-*O*-β-[d]{.smallcaps}-glucuronideC~21~H~18~O~13~478.0747\[[@CR24]\]36Quercetin-3-*O*-β-[d]{.smallcaps}-glucuronide methyl esterC~22~H~20~O~13~492.0904\[[@CR24]\]37Quercetin-3-*O*-β-[d]{.smallcaps}-(6-n-butyl glucuronide)C~25~H~25~O~13~533.1295\[[@CR15]\]38(−)-Epicatechin-3-*O*-gallateC~22~H~18~O~10~442.0900\[[@CR15]\]39IsoquercitrinC~21~H~20~O~12~464.0955\[[@CR80]\]Tannins40Gallic acidC~7~H~6~O~5~170.0215\[[@CR74]\]417-*O*-Galloyl-[d]{.smallcaps}-sedoheptuloseC~14~H~18~O~11~362.0849\[[@CR19]\]42Gemin DC~27~H~22~O~18~634.0806\[[@CR6], [@CR7]\]43Oenothein CC~34~H~24~O~22~784.0759\[[@CR6], [@CR7]\]443-*O*-Galloyl-[d]{.smallcaps}-glucoseC~13~H~16~O~10~332.0743\[[@CR6], [@CR7]\]452,3-Di-*O*-galloyl-[d]{.smallcaps}-glucoseC~20~H~20~O~14~484.0853\[[@CR6], [@CR7]\]461,2,3-Tri-*O*-galloyl-β-[d]{.smallcaps}-glucoseC~27~H~24~O~18~636.0963\[[@CR6], [@CR7]\]471,2,6-Tri-*O*-galloyl-β-[d]{.smallcaps}-glucoseC~27~H~24~O~18~636.0963\[[@CR6], [@CR7]\]481,2,3,6-Tetra-*O*-galloyl-β-[d]{.smallcaps}-glucoseC~34~H~28~O~22~788.1072\[[@CR6], [@CR7]\]49Tellimagrandin IC~34~H~26~O~22~786.0916\[[@CR6], [@CR7]\]50Tellimagrandin IIC~41~H~30~O~26~938.1025\[[@CR6], [@CR7]\]51Isocoriariin FC~34~H~26~O~23~802.0865\[[@CR6], [@CR7]\]52Coriariin FC~34~H~26~O~23~802.0865\[[@CR6], [@CR7]\]53Rugosin BC~41~H~30~O~27~954.0974\[[@CR6], [@CR7]\]54Isorugosin BC~41~H~30~O~27~954.0974\[[@CR6], [@CR7]\]55IsoterchebinC~41~H~30~O~27~954.0974\[[@CR6], [@CR7]\]56Isorugosin AC~48~H~34~O~31~1106.1084\[[@CR6], [@CR7]\]57Rugosin DC~82~H~58~O~52~1874.1894\[[@CR6], [@CR7]\]58Isorugosin DC~82~H~58~O~52~1874.1894\[[@CR6], [@CR7]\]59Camptothin AC~61~H~46~O~40~1418.1565\[[@CR6], [@CR7]\]60Camptothin BC~75~H~54~O~48~1722.1785\[[@CR6], [@CR7]\]61Cornusiin BC~48~H~30~O~30~1086.0822\[[@CR6], [@CR7]\]62Cornusiin AC~68~H~50~O~44~1570.1675\[[@CR6], [@CR7]\]63Cornusiin DC~75~H~54~O~48~1722.1785\[[@CR6], [@CR7]\]64Cornusiin EC~82~H~58~O~52~1874.1894\[[@CR6], [@CR7]\]65Cornusiin FC~95~H~70~O~62~2202.2325\[[@CR6], [@CR7]\]66Cornusiin CC~102~H~74~O~66~2354.2434\[[@CR6], [@CR7]\]67Methyl tri-*O-*methylgallateC~11~H~14~O~5~226.0841\[[@CR6], [@CR7]\]68Dimethyl hexamethoxydiphenateC~22~H~26~O~10~450.1526\[[@CR6], [@CR7]\]69Trimethyl-octa-*O*-methylvaloneateC~32~H~36~O~15~660.2054\[[@CR6], [@CR7]\]Polysaccharides70Co-4\[[@CR8]\]71COP-1\[[@CR9]\]72COP-2\[[@CR9]\]73COP-3\[[@CR9]\]74COP-4\[[@CR9]\]75FCAP1\[[@CR81]\]76FCP5-A\[[@CR8]\]77PFCA-III\[[@CR8]\]78PFCC-I\[[@CR8]\]79SZYP-2\[[@CR8]\]Other compounds80Phenylpropanoids*p*-Hydroxycinnamic acidC~9~H~8~O~3~164.0473\[[@CR74]\]81Caffeic acidC~9~H~8~O~4~180.0423\[[@CR15]\]82Caftaric acid monomethyl esterC~14~H~14~O~9~326.2556\[[@CR15]\]83Caffeoyltartaric acid dimethyl esterC~15~H~16~O~9~340.0794\[[@CR76]\]84Sterolsβ-SitosterolC~29~H~50~O414.7067\[[@CR15]\]85Daucosterol-6′-malateC~39~H~64~O~10~692.4499\[[@CR80]\]86Carboxylic acidsSuccinic acidC~4~H~6~O~4~118.0266\[[@CR85]\]87Malic acidC~4~H~6~O~5~134.0215\[[@CR85]\]88Methylmalic acidC~5~H~8~O~5~148.0372\[[@CR74]\]89Citric acidC~6~H~8~O~7~192.0270\[[@CR85]\]90Butoxysuccinic acidC~8~H~14~O~5~190.1938\[[@CR15]\]91Furans5-HydroxymethylfurfuralC~6~H~6~O~3~126.0317\[[@CR73]\]92Dimethyltetrahydrofuran cis-2,5-dicarboxylateC~8~H~12~O~5~188.0685\[[@CR79]\]93Mineral substancesCa, Fe, K, Mg, Mn, Zn\[[@CR82]\] Fig. 2Structures of chemical constituents from *Corni Fructus* Fig. 3Structures of chemical constituents from *Corni Fructus* Fig. 4Structures of chemical constituents from *Corni Fructus* Fig. 5Structures of chemical constituents from *Corni Fructus*

Terpenoids (**1**--**26**) and flavonoids (**27**--**39**) {#Sec3}
----------------------------------------------------------

Most terpenoids and flavonoids in CF shared two similar isolation processes. Firstly, CF was percolated with ethanol to acquire the solvent which was then evaporated under reduced pressure. The resulting extract was suspended in water and then partitioned with ethyl acetate for several times. Finally, the extract was subjected to column chromatography over silica gel to yield compounds. Secondly, CF was grounded into powder and then subjected to supercritical carbon dioxide to yield extract. The resulting extract was subjected to GC--MS to identify the chemical components. So far, 26 terpenoids and 13 flavonoids have been isolated and identified from CF. Among terpenoids, the pharmacological activities of sweroside (**1**), loganin (**5**), cornuside (**23**), ursolic acid (**24**), and oleanolic acid (**25**) have been further assayed, and a wide range of pharmacological activities has been revealed. Furthermore, two types of flavonoids namely kaempferol (**28**), quercetin (**33**), and their derivatives are the essential flavonoids.

Tannins (**40**--**69**) {#Sec4}
------------------------

During the isolation process, CF was firstly homogenized in acetone and then filtered to acquire an aqueous solution which was sequentially extracted with diethyl ether and ethyl acetate. The extract was subjected to column chromatography to give compounds. Finally, the chemical structure and molecular weight were determined using nuclear magnetic resonance (NMR) spectroscopy. To date, 30 tannic acids have been isolated from CF. Tsutomu HATANO identified 28 of them. Many tannic acids in this Chinese herb have the large molecular weight, e.g., the molecular weight of Cornusiins A--F and Camptothins A--B are even larger than 1000 Da \[[@CR6], [@CR7]\], because dimers and trimers exist in these types of tannic acids.

Polysaccharides (**70**--**79**) {#Sec5}
--------------------------------

Wu and Yin identified most polysaccharides in CF \[[@CR8], [@CR9]\]. In their isolation process, hot water or petroleum ether was initially used for combining with assistant ultrasonic and microwave to break the cell wall to isolate polysaccharides. Further separation and purification were achieved by the combination of several techniques, e.g., fractional precipitation, ethanol precipitation, ion-exchange chromatography and affinity chromatography. Finally, infrared spectroscopy analysis and morphological analysis were used to determine the physiochemical and structural features of the polysaccharide.

Other compounds (**80**--**93**) {#Sec6}
--------------------------------

Four phenylpropanoids, two sterols, five carboxylic acids, two furans, and several mineral substances have also been determined. Among them, 5-hydroxymethylfurfural exhibits diverse biological activities. Besides, Chen, Li, and Wen identified 32, 16, and 48 volatile compounds by GC--MS, respectively \[[@CR10]--[@CR12]\].

Pharmacological activities {#Sec7}
==========================

Although just a few chemical constituents from CF are assayed for their biological activities, these components displayed diverse pharmacological activities. Detailed biological activities are summarized in Table [2](#Tab2){ref-type="table"}.Table 2Summary of pharmacological activities of CFExtracts or compoundsDisease modelsSpecific effectsReferencesHypoglycemic activity Oleanolic acidFasting ratDecrease plasma glucose levels. Regulate ACh release from nerve terminals to activate muscarinic M3 receptors in the pancreatic cells and increase C-peptide and insulin release\[[@CR83]\] Iridoid glycosidesSTZ-induced rat as DM modelShow α-glucosidase inhibition activity in vitro and decrease serum glucose levels in vivo\[[@CR16]\] Loganin\
 Morroniside\
 Ursolic acidSTZ-induced mice as DM model, HepG2 cell linesShow α-glucosidase inhibition activity in vitro. Decrease fasting blood glucose and alleviate weight loss, polydipsia, and polyphagia. Increase SOD activity and ROS scavenging activity. Attenuate aldose reductase activity and decrease MDA plasma level and renal somatic indices in mice\[[@CR14]\] Butyl morroniside\
 (−)-Epicatechin-3-*O*-gallate\
 Caftaric acid monomethyl esterHigh glucose-induced BRIN-BD11 and H4IIE cell lines as in vitro DM modelIncrease glucose uptake efficiency. Reduce PEPCK mRNA level and NO production. Inhibit pancreatic β-cell death\[[@CR15]\] Aqueous extractSTZ-induced rat as diabetic organs injury modelDecrease levels of glucose and TC in serum, and α-SMA expression in kidney. Improve the pathohistological injury of pancreas, kidney, lung, and liver\[[@CR13]\] Aqueous extractNormal ratShow α-glucosidase inhibition activity in vitro, and exhibit hypoglycemic effect via oral sucrose tolerance test in vivo\[[@CR17]\] Aqueous extractDexamethasone and 8-bromo-cAMP-induced BRIN-BD11 and H4IIE cell lines as in vitro DM modelIncrease insulin release. Decrease PEPCK mRNA level\[[@CR18]\]Nephroprotective activity LoganinSTZ-induced rat and high glucose-induced HK-2 as in vivo and in vitro diabetic nephropathy modelImprove renal function. Decrease CTGF level in kidney and serum via ERK signaling pathway\[[@CR23]\] Morroniside\
 Loganin\
 7-*O*-Galloyl-[d]{.smallcaps}-sedoheptuloseDb/db mice as obesity-associated type 2 diabetic nephropathy modelSuppress formation of AGEs and TBARS in the kidney. Reduce the production of SREBP-1&2, NF-κB p65, COX-2, and iNOS. Decrease GSH/GSSG ratio and levels of serum glucose, TC, and TG\[[@CR19]\] 7-*O*-Galloyl-[d]{.smallcaps}-sedoheptuloseSTZ-induced rat as diabetic nephropathy modelDecrease serum creatinine, renal glucose, and urinary protein. Reduce the production of AGE, RAGE, HO-1, intracellular glycation, CML, GA-pyridine, and TBARS\[[@CR21]\] Iridoid glycosidesSTZ-induced rat as diabetic nephropathy modelSuppress over-deposition of fibronectin and laminin in the kidney. Reduce protein and mRNA levels of TGF-β1 in serum and glomeruli\[[@CR25]\] Iridoid glycosides\
 Triterpene acidsDb/db mice as obesity-associated type 2 diabetic nephropathy modelImprove the histological injury of kidney and pancreas. Ameliorate the structural alterations in mesangial cells and the podocytes in the renal cortex. Inhibit ECM accumulation in the kidney. Decrease 24 h urine protein and serum levels of urea nitrogen and creatinine. Increase insulin release, and decrease fasting blood glucose and levels of TC, TG, and GSP. Attenuate food consumption, water intake, and urine volume. Reduce the production of RAGE, NF-κB, SphK1, and TGF-β\[[@CR22]\] CF extractSTZ-induced rat as diabetic nephropathy modelInhibit AGE formation in the kidney. Attenuate hyperglycemia and proteinuria. Reduce the production of RAGE, NF-κB, TGF-β1, and CML\[[@CR20]\] Ethanol extractHigh glucose-induced mesangial cells as in vitro diabetic nephropathy modelDecrease the production of Col V, FN, and IL-6\[[@CR24]\]Myocardial protection activity MorronisideHigh glucose-induced rat as diabetic cardiomyopathy modelInhibit myocardial cell apoptosis. Elevate Bcl-2 production and decrease expressions of Bax and caspase-3\[[@CR28]\] Triterpene acidsSTZ-induced rat as diabetic cardiomyopathy modelInhibit the ventricular remodeling and regulate the systolic and diastolic function of the left ventricle. Increase insulin release and reduce serum glucose levels. Enhance GSX and SOD activity. Increase the production of calstabin 2, PLB, and SERCA2a. Decrease protein and mRNA levels of ECE, iNOS, MDA, ET-1, and propreET-1\[[@CR26]\]Testis-protective activity Iridoid glycosidesSTZ-induced rat as diabetic testicular damage modelImprove the pathohistological injury of testes and pancreas. Increase serum insulin release and decrease blood glucose levels. Alleviate weight loss, polydipsia, polyphagia, and polyuria. Increase CAT and SOD activity. Reduce the production of AGEs, RAGE, ROS, MDA, and p-p38 MAPK. Down-regulate Bax/Bcl-2 ratio and spermatogenic cell apoptosis\[[@CR27]\]Antioxidant activity MorronisideHydrogen peroxide-induced SH-SY5Y cell line as in vitro neurodegenerative disorder modelSuppress intracellular accumulation of Ca^2+^. Increase SOD activity and reduce the loss of MMP. Inhibit cytotoxicity\[[@CR29]\] MorronisideHigh ambient glucose-induced endothelial cell injury modelAttenuate cellular morphological damage. Repair cell cycle progression and improve cell viability\[[@CR35]\] Ursolic acidHydrogen peroxide-induced HEI-OC1 cell line as in vitro inner ear diseases modelIncrease antioxidant enzymes expressions, e.g., CAT and GPX. Suppress lipid peroxidation\[[@CR32]\] 5-HydroxymethylfurfuralHigh glucose-induced HUVECs as in vitro oxidative stress modelDecrease levels of ROS, IL-8, JNK1, and JNK2/3. Increase P-Akt production\[[@CR34]\] Total saponinsSTZ-induced rat as a diabetic oxidative stress modelRegulate NO release and endothelium-dependent relaxation on the mesenteric artery. Reduce blood glucose levels\[[@CR30]\] Aqueous extractHypoxanthine and xanthine oxidase-induced bovine PAECs as in vitro oxidative stress modelRegulate GSH redox cycle. Increase the intracellular GSH production and the activity of GSH peroxidase and GSH disulfide reductase. Reduce the intracellular level of GSH disulfide. Increase CAT and SOD activity and inhibit the production of hydrogen peroxide and superoxide anion\[[@CR31]\] Ethanol extractLPS-induced RAW 264.7 macrophage cells as in vitro oxidative stress modelAttenuate xanthine oxidase activity and ROS production. Induce the production of antioxidant enzymes, e.g., CAT, GSX, Cu/Zn-SOD, and Mn-SOD\[[@CR33]\]Anti-inflammatory activity CornusideTNF-α-induced HUVECs as in vitro inflammation modelDecrease the production of ICAM-1, VCAM-1, MCP-1, and NF-κB. Inhibit NF-κB p65 translocation\[[@CR36]\] CornusideLPS-induced RAW 264.7 macrophage cells as in vitro inflammation modelDecrease the production of COX-2, iNOS, PGE~2~, NO, IL-1β, IL-6, and TNF-α. Suppress the translocation of NF-κB p65, the phosphorylation and degradation of IκB-α, and the phosphorylation of ERK1/2, JNK1/2, and p38\[[@CR38]\] Aqueous extractLPS-induced RAW 264.7 macrophage cells as in vitro inflammation modelDecrease protein and mRNA levels of COX-2 and iNOS. Reduce PGE~2~ and NO production\[[@CR37]\]Anticancer activity Aqueous extractHSC-2, HSC-3, HSC-4, Ca9-22, NA cell lines as in vitro oral squamous cell carcinoma modelProduce broad radical peak under alkaline condition and increase the cytotoxicity and superoxide anion scavenging activity of vitamin C\[[@CR39]\] Aqueous extractE2-induced MCF-7 cell line as in vitro ER^+^ human mammary carcinoma modelInhibit cell line anchorage-independent growth and reduce the mitogenically inert metabolite E3 formation\[[@CR40]\] Aqueous extractParental ER^+^ MCF-7 cell line as in vitro human mammary carcinoma modelSuppress cell line anchorage-independent growth and induce G1 or G2/M arrest and apoptosis. Increase anti-proliferative E2 metabolites production\[[@CR41]\] Aqueous extractHepG2, SKHep1 and PLC/PRF/5 cell lines as in vitro hepatocellular carcinoma modelInhibit cell proliferation. Exhibit free radicals scavenging activity and suppress lipid peroxidation and xanthine oxidase production\[[@CR42]\]Neuroprotective activity Cornuside\
 1,2,3-Tri-*O*-galloyl-β-[d]{.smallcaps}-glucose\
 1,2,3,6-Tetra-*O*-galloyl-β-[d]{.smallcaps}-glucose\
 Tellimagrandin I\
 Tellimagrandin II\
 IsoterchebinIn vitro enzyme activities assayExhibit synergetic inhibitory activities against BACE1 and ChE\[[@CR45]\] MorronisideMCAO-induced rat as focal cerebral ischemia modelDecrease the infarction volume and improve neurological function. Increase GSH expression and SOD activity. Decrease the production and activity of MDA and caspase-3 in ischemic cortex tissues\[[@CR47]\] 5-HydroxymethylfurfuralHydrogen peroxide-induced rat hippocampal neurons as in vitro neurodegenerative disorder modelEnhance Bcl-2 production and suppress expressions of Bax, caspase-3, and p53\[[@CR84]\] Iridoid glycosidesMCAO-induced rat as focal cerebral ischemia modelImprove neurological function. Increase the number of BrdU-positive cells and nestin-positive cells in the subventricular zone, and the number of new mature neurons and blood vessels in the striatum. Increase protein and mRNA levels of VEGF and Flk-1\[[@CR46]\] Iridoid glycosidesFimbria-fornix transected rat as cerebral ischemia modelDecrease neuron loss in the hippocampus and improve memory deficits. Increase the production of BDNF, NGF, Bcl-2, SYP, Trk A, and GAP-43, and decrease the production of Bax and Cyt c\[[@CR49]\] 7*R*-*O*-Methyl-morroniside\
 7*S*-*O*-Methyl-morroniside\
 7-*O*-Butyl-morroniside\
 Loganin\
 MorronisideGlutamate-induced HT22 cell lines as in vitro hippocampal cell injuryImprove cell viability\[[@CR43]\] Iridoid glycosides*Mycobacterium tuberculosis* and guinea-pig myelin basic protein-induced experimental autoimmune encephalomyelitis rat as multiple sclerosis modelIncrease the number of mature oligodendrocytes and reduce the number of oligodendrocyte progenitor cells. Inhibit the process of T cell entry to the central nervous system and attenuate microglia activation. Increase BDNF expression and decrease phosphorylation of JAK/STAT1/3 and inflammatory cytokines production, e.g., IL-1β, IFN-γ, TNF-α\[[@CR48]\] Iridoid glycosides*Mycobacterium tuberculosis* and myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis mouse as multiple sclerosis modelDecrease BDNF and NGF loss in the spinal cord\[[@CR50]\] Aqueous extractPC 12 cell linesIncrease cell neurite outgrowth. Inhibit extracellular Ca^2+^ influx, and protein and mRNA levels of STIM1\[[@CR44]\]Hepatoprotective activity 5-HydroxymethylfurfuralHydrogen peroxide-induced L02 cell lines as in vitro hepatitis modelPromote S phase into G2/M phase and recover cell cycle to normal. Reduce NO production and caspase-4 activity and inhibit hepatocyte apoptosis\[[@CR51]\] 5-HydroxymethylfurfuralHydrogen peroxide-induced L02 cell lines as in vitro hepatitis modelImprove hepatocyte morphology and reduce caspase-3&9 expressions\[[@CR52]\] 5-Hydroxymethylfurfural[d]{.smallcaps}-Galactosamine/TNF-α-induced L02 cell lines as in vitro acute liver injury modelInhibit hepatocyte apoptosis. Increase Bcl-2 production and decrease intracellular Ca^2+^ level and production of ATF4, Bax, CHOP, PERK, and p-eIF2α\[[@CR53]\] 7-*O*-Galloyl-[d]{.smallcaps}-sedoheptuloseDb/db mice as obesity-associated type 2 diabetic liver injury modelImprove hepatic histological damage and decrease serum levels of ALT, AST, and blood glucose. Attenuate water intake, food consumption, and body weight gain. Decrease the production of AP-1, NF-κB p65, IL-6, TNF-α, ICAM-1, MCP-1, AGEs, RAGE, GA-pyridine, pentosidine, CEL, CMA, CML, leptin, resistin, p-ERK1/2, and p-JNK\[[@CR54]\] Ethanol extractAcetaminophen-induced mice as liver injury modelIncrease levels of CAT, HO-1, and SOD. Suppress lipid peroxidation\[[@CR55]\]Improving osteoporosis activity SwerosideRat osteoblasts and human MG-63 cell linesStimulate the osteocalcin secretion. Increase cell proliferation and inhibit apoptotic cell death. Increase ALP activity\[[@CR56]\] CF extractRANKL-induced mice BMDM as in vitro osteoclast differentiation modelSuppress osteoclast differentiation. Reduce protein and mRNA levels of c-Fos, NFATc1, OSCAR, and TRAP. Inhibit phosphorylation of p-38 and c-JNK and degradation of I-κB\[[@CR57]\]Promoting melanogenesis activity Methanol extractMelan-a cell linesIncrease the production and activity of tyrosinase. Increase MITF-M mRNA level and TRP-1&2 production\[[@CR58]\]Immunomodulatory activity Aqueous extractC57BL/6 mice are transplanted with a skin graft from Balb/C donorsProlong skin allograft survival. Reduce the number of graft-infiltrating T cells and inhibit their proliferation. Decrease intracellular IL-12 expression by intragraft DCs and IFN-γ expression by graft-infiltrating T cells. Reduce intragraft IL-12 mRNA level\[[@CR59]\]Lung-protective activity Oleanolic acid\
 Ursolic acidEpidermal growth factor---and phorbol ester‐induced NCI‐H292 cell lines as in vitro airway diseases modelDecrease protein and mRNA levels of MUC5AC mucin\[[@CR60]\] Aqueous extractOvalbumin-induced BALB/c mice as allergic asthma modelInhibit eosinophil infiltration and ameliorate allergic airway inflammation and airway hyperresponsiveness. Decrease the production of IL-5&13 and OVA-specific IgE\[[@CR61]\]Vasorelaxation activity CornusidePhenylephrine-contracted rat aorta and HUVECDilate vascular smooth muscle in the rat and increase cGMP production in vitro\[[@CR62]\]Antiviral activity Aqueous extractCVA16 infected Vero cells as in vitro HFMD modelInhibit CVA16 replication\[[@CR63]\]

Hypoglycemic activity and diabetic target organs protective activity {#Sec8}
--------------------------------------------------------------------

Diabetes mellitus (DM) is a group of long-term and chronic metabolic disorders which are associated with high serum glucose levels. Compared with the no treatment diabetic animal model group, CF extract (at 300 mg kg^−1^ 2 day^−1^ and 400 mg kg^−1^ day^−1^ p.o.), loganin, morroniside, and ursolic acid (each at 200 mg kg^−1^ day^−1^ p.o.) for 4 weeks can significantly decrease fasting blood glucose and alleviate polyphagia, polydipsia, polyuria, and weight loss \[[@CR13], [@CR14]\]. In He's study, metformin (at 200 mg kg^−1^ day^−1^ p.o.) demonstrated better effect \[[@CR14]\]. Besides, loganin, morroniside, ursolic acid, and butyl morroniside (each at 100 μmol L^−1^) can protect the pancreatic β-cells from high glucose-induced excessive oxidative stress and apoptosis \[[@CR14], [@CR15]\], may further increase the insulin release. Compared with the insulin treatment, CF extract, (−)-epicatechin-3-*O*-gallate, and caftaric acid monomethyl ester (each at 50 μmol L^−1^) can also significantly inhibit α-glucosidase activity to slow down the elevation of serum glucose levels \[[@CR14], [@CR16], [@CR17]\] and suppress the hepatic gluconeogenesis by decreasing the protein and mRNA levels of PEPCK in vitro \[[@CR15], [@CR18]\].

Also, CF extract, iridoid glycosides, and the single compound can decrease 24 h urine protein and serum levels of urea nitrogen and creatinine. To be specific, loganin, morroniside, and 7-*O*-galloyl-[d]{.smallcaps}-sedoheptulose (each at 20--100 mg kg^−1^ day^−1^ p.o.) for 10 days and 8 weeks can significantly inhibit both AGE/RAGE formation \[[@CR19]--[@CR22]\] and CTGF production \[[@CR23]\] in db/db mice or STZ-induced diabetic nephropathy model. They can also significantly alleviate diabetic organ injury by decreasing the production of NF-κB and its downstream synthetases and cytokines \[[@CR19]--[@CR25]\], increasing antioxidant enzyme production \[[@CR19], [@CR26], [@CR27]\], and suppressing apoptotic cell death \[[@CR27], [@CR28]\].

Antioxidant activity {#Sec9}
--------------------

Long-term oxidative stress will generate excessive ROS to oxidize protein, lipids, DNA and then cause cell death, tissue damage, and organ dysfunction. Ideal antioxidant drugs are required to regulate the defense system and scavenge excessive ROS. Studies indicated that morroniside (at 1, 10, 100 μmol L^−1^) for 24 h and total saponins (at 60 and 120 mg kg^−1^ day^−1^ p.o.) for 4 weeks regulated Ca^2+^ and NO release \[[@CR29], [@CR30]\], the aqueous extract (at 0.25--2.0 mg mL^−1^) for 20 h modulated GSH redox cycle \[[@CR31]\], the aqueous extract, the ethanol extract (at 0.01--0.1 mg mL^−1^), morroniside (at 0.05--2 µg mL^−1^), and ursolic acid (at 0.05--2 µg mL^−1^) for 24 h promoted antioxidant enzymes syntheses \[[@CR31]--[@CR33]\] to inhibit lipid peroxidation \[[@CR29]\], 5-hydroxymethylfurfural (at 100--400 μmol L^−1^) for 3 days decreased ROS release \[[@CR34]\], morroniside (at 100 μmol L^−1^) for 2 days recovered cell cycle to normal state \[[@CR35]\]. Mentioned effects significantly together reduced the oxidative stress-induced damages compared with the no treatment group.

Anti-inflammatory activity {#Sec10}
--------------------------

Prolonged and incurable inflammation may cause many diseases, e.g., atherosclerosis, cancer, ulcerative colitis. In LPS and TNF-α-induced cell inflammation models, compared with the no treatment group, CF aqueous extract (at 0.2, 1, 5 mg mL^−1^) and cornuside (at 1, 10, 50 μmol L^−1^) for 24 h significantly inhibited NF-κB p65 translocation, down-regulated COX-2 and iNOS production, finally decreased PGE~2~ and NO levels to control excessive inflammatory responses \[[@CR36]--[@CR38]\].

Anticancer activity {#Sec11}
-------------------

CF aqueous extract significantly enhanced both the cytotoxicity and superoxide anion scavenging activity of vitamin C at 0.5 and 36 µg mL^−1^, respectively. Together with CF aqueous extract, vitamin C further inhibited proliferation and induced apoptosis in several human oral squamous cell carcinoma cell lines. Compared with no treatment, the proliferation inhibition rate was at 1.3--71.0% \[[@CR39]\]. Furthermore, the aqueous extract (at 1.0 mg mL^−1^) for 2 days significantly exhibited anti-ER^+^ human mammary carcinoma activity by inhibiting cell anchorage-independent growth, regulating the metabolism of E2 and E3 \[[@CR40]\], and influencing cell cycle progression and cellular apoptosis \[[@CR41]\]. Finally, the aqueous extract has been tested for its cancer inhibitory effect in several hepatocellular carcinomas and leukemic cell lines. The study indicated that the aqueous extract inhibited the tumor cell proliferation in a dose-dependent manner at 0.11--0.337 mg mL^−1^, exhibited oxygen free radicals scavenging activity (at 50 µg mL^−1^), attenuated xanthine oxidase production (at 2.62 mg mL^−1^) and lipid peroxidation (at 0.892 mg mL^−1^) \[[@CR42]\]. In this study, CF aqueous extract exhibited the similar effects compared with 5-fluorouracil (at 0.5, 1, 5 µg mL^−1^).

Neuroprotective activity {#Sec12}
------------------------

Many compounds in CF were further tested for the neuroprotective effects. 7*R*-*O*-Methyl-morroniside, 7*S*-*O*-methyl-morroniside, 7-*O*-butyl-morroniside, loganin, and morroniside (each at 10 and 50 μmol L^−1^) for 1 h significantly protected the neurons against glutamate-induced neurotoxicity up to about 78% compared with the no treatment group \[[@CR43]\]. CF aqueous extract (at 60 µg mL^−1^) significantly inhibited the extracellular Ca^2+^ influx to increase cell neurite outgrowth \[[@CR44]\]. Also, cornuside, isoterchebin, and tellimagrandin II (each at 25--100 μmol L^−1^) displayed anti-Alzheimer's disease potential due to their synergetic inhibitory activities against BACE1 and ChE \[[@CR45]\].

Cerebral ischemia, multiple sclerosis, and neurodegenerative disorder models are applied in animal experiments. Iridoid glycosides (at 60 and 180 mg kg^−1^ day^−1^ p.o.) for 1--4 weeks and morroniside (at 90 and 270 mg kg^−1^ day^−1^ p.o.) for 3 days significantly decreased the infarction volume, increased the number of new mature neurons and blood vessels, and improved nervous system function \[[@CR46], [@CR47]\]. Also, iridoid glycosides (at 50--180 mg kg^−1^ day^−1^ p.o.) for 3--4 weeks can significantly promote NGF and BDNF production \[[@CR48]--[@CR50]\], and repair the abnormal functions of microglia, oligodendrocyte, and T cell to maintain the central nervous system homeostasis \[[@CR48]\].

Hepatoprotective activity {#Sec13}
-------------------------

In hepatitis cell models, 5-hydroxymethylfurfural (at 0.2--1 and 0.79 μmol L^−1^) for 24 h has been shown to protect hepatocytes from H~2~O~2~ induced-cytotoxicity by significantly decreasing NO and intracellular Ca^2+^ levels, inhibiting abnormal production of apoptosis-related proteins and recovering back to regular cell cycle \[[@CR51]--[@CR53]\]. In hepatitis animal models, 7-*O*-galloyl-[d]{.smallcaps}-sedoheptulose (at 20 and 100 mg kg^−1^ day^−1^ p.o.) for 6 weeks and CF ethanol extract (at 100--500 mg kg^−1^ day^−1^ p.o.) for 1 week significantly decreased the serum marker enzymes of hepatic damage, weakened the oxidative stress by promoting antioxidant enzymes production and inhibiting lipid peroxidation, finally improved hepatic histological injury \[[@CR54], [@CR55]\].

Other pharmacological activities {#Sec14}
--------------------------------

In addition to the mentioned pharmacological activities, CF has also been reported to exert multiple bioactivities. Firstly, sweroside (at 7.5 µg mL^−1^) for 1 week significantly promoted the proliferation and differentiation of osteoblasts via the regulation of osteocalcin \[[@CR56]\]. Also, CF extract (at 0--100 µg mL^−1^) for 4 days significantly inhibited osteoclast differentiation in a dose-dependent manner via the inhibition of the signaling cascades NF-κB/c-Fos/NFATc1 to improve osteoporosis \[[@CR57]\]. Secondly, CF methanol extract (at 3.125--12.5 µg mL^−1^) for 3 days significantly up-regulated synthesis and activity of tyrosinase, raised TRP-1&2 translation associating with increasing transcription of MITF-M, finally promoted melanogenesis by 36.1% \[[@CR58]\]. Thirdly, CF aqueous extract possesses immunomodulatory activity. In C57BL/6 mice that were transplanted with a skin graft from Balb/C donors, CF extract significantly prolonged skin allograft survival synergistically by suppressing Th1 response, promoting regulatory T cell generation, and enhancing its suppressive function \[[@CR59]\]. Fourthly, CF shows lung-protective activity via two studies. In the cellular test, oleanolic acid (at 10 and 100 μmol L^−1^) and ursolic acid (at 100 μmol L^−1^) for 30 min' pretreatment significantly down-regulated MUC5AC mucin whose excessive level would impair airway defenses to cause serious airway diseases \[[@CR60]\]. In an animal experiment, CF aqueous extract (at 50 and 200 mg kg^−1^ 3 day^−1^ p.o.) for 5 weeks significantly decreased the production of inflammatory mediators and reduced eosinophil infiltration, finally attenuated allergic airway inflammation and airway hyperresponsiveness \[[@CR61]\]. Fifthly, cornuside significantly dilated vascular smooth muscle in phenylephrine-contracted rat aorta via the up-regulation of cGMP level to show its vasorelaxation activity \[[@CR62]\]. Finally, among in vitro screening of antiviral drugs for treating hand, foot, and mouth disease (HFMD) infection, CF aqueous extract (at 0.4 µg mL^−1^) for 2 days significantly inhibited CVA16 replication in cellular level \[[@CR63]\].

Conclusion {#Sec15}
==========

CF is recognized as a fundamental constituent part of tonifying Yin and Yang prescription because of its harmonious and complementary features according to the basic theory of TCM. It possesses the properties of sour and astringent. Firstly, sour and sweet herbs can be combined to nourish Yin, it can act as the sovereign and ministerial drug among *Radix Rehmanniae Praeparata*, *Dioscoreae Rhizoma*, *Lycii Fructus*, *Ligustri Lucidi Fructus*, *Schisandrae Chinensis Fructus*. Also, sour and astringent properties exhibit their function of astringing and storing. It also behaves as the sovereign and the ministerial drug that combines with *Euryales Semen*, *Sepiae Endoconcha*, *Mantidis Oötheca*, *Rubi Fructus*, *Paeoniae Radix Alba* to treat spermatorrhea, urorrhagia, metrorrhagia and metrostaxis, and excessive perspiration. Finally, CF can be as the adjuvant and conductant drug to alleviate warm and dry features of Yang-reinforcing drugs.

Chemical constituents from terpenoids, flavonoids, tannins, and furans exhibited diverse biological activities, including hypoglycemic, neuroprotective, heart-protective, hepatoprotective, nephroprotective, testis-protective activities. Pharmacological activities are outlined in Fig. [6](#Fig6){ref-type="fig"}. In these studies, bioactive components from CF mainly alleviated the damage of target organs by antioxidant activity, anti-inflammatory activity, and anti-apoptosis activity, i.e., up-regulating the expressions and activities of antioxidant enzymes, down-regulating the levels of cytokines and chemokines, and modulating the abnormal expressions of apoptotic death associated proteins.Fig. 6The various pharmacological activities of the extract and chemical compounds identified from *Corni Fructus*

Hypoglycemic activity and alleviating diabetic target organs damage are critical pharmacological activities among the broad spectrum of pharmacological activities of CF. Morroniside, loganin, oleanolic acid, ursolic acid, and 7-*O*-galloyl-[d]{.smallcaps}-sedoheptulose exhibited the similar efficacy compared with the conventional oral hypoglycemic drugs (acarbose and metformin). In vivo studies, they reduced serum glucose levels and alleviated unusual symptoms caused by diabetes. In cellular assays, they protected pancreatic β cell from oxidative damage, increased insulin release, improved insulin resistance, displayed α-glucosidase inhibition activity, and suppressed liver gluconeogenesis. Also, compounds alleviated the high-glucose triggered target organs damage by attenuating oxidative stress, inflammation, and apoptosis, finally kept the essential function of target organs stable. CF has also been widely used to treat DM in clinical work. For example, Jingui Shenqi Wan and Liuwei Dihuang Wan are two classic Chinese medicinal formulae which contain CF. Clinical trials indicated that Jingui Shenqi Wan and Liuwei Dihuang Wan could decrease serum glucose levels, alleviate typical DM symptoms and repair target organs injury \[[@CR64]--[@CR67]\]. Diverse anti-diabetes and anti-diabetic complication pharmacological activities make CF a potential herb to become the complementary drug for treating DM.

Another significant biological activity is the neuroprotection. In cerebral ischemia rat model and neurodegenerative disorder cellular model, iridoid glycosides (e.g., morroniside) and 5-hydroxymethylfurfural increased the number of new mature neurons and blood vessels and exerted anti-oxidative stress, anti-inflammation, and anti-apoptosis properties. In cerebral ischemia rat model and multiple sclerosis rats and mice models, iridoid glycosides also enhanced the levels of brain-derived neurotrophic factor and nerve growth factor. Current studies showed that the pathogenic mechanisms of neurodegenerative diseases have the close relationship with autophagy deficiency and abnormal proteins aggregate clearance dysfunction \[[@CR68], [@CR69]\]. In addition to the anti-apoptotic activity, pharmacological activities of CF on the regulation of autophagy can be further explored. Furthermore, many classic Chinese medicinal formulae have been used to treat neurological disorders belonging to liver and kidney deficiency \[[@CR70]--[@CR72]\]. For example, Liuwei Dihuang Wan treats insomnia, Zuogui Wan (左归丸) treats epilepsy and vertigo, Dabu Yinjian (大补阴煎) treats a headache, Zuogui Wan and Dihuang Yinzi (地黄饮子) treats stroke, and Huanshao Dan (还少丹) treats dementia. CF plays a vital role in nourishing liver and kidney Yin in these Chinese medicinal formulae.

However, about 90 compounds have been isolated and identified from CF, only 18% compounds are further assayed for their pharmacological activities in vivo and in vitro. It indicates that pharmacological activities of the remaining 90% chemical components are still unknown yet. Moreover, current studies do not provide enough evidence to verify the drug binding sites of active ingredients of CF. For example, it is difficult to judge whether these active ingredients bind the G protein coupled receptor, ion channels, transmembrane receptor kinases, or nuclear receptors to work. Therefore, more systematic and detailed pharmacological studies on CF need to be fulfilled in the future.
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